South Korean (KOSPI) Healthcare Services Industry Analysis

Industry Valuation and Performance

Has the South Korean Healthcare Services Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE
Fri, 21 Jan 2022	₩13.3t	₩2.6t	₩228.6b	8.6x
Sun, 19 Dec 2021	₩15.5t	₩2.6t	₩228.6b	8.7x
Tue, 16 Nov 2021	₩17.4t	₩2.6t	₩210.5b	13.4x
Thu, 14 Oct 2021	₩16.8t	₩2.6t	₩210.5b	13.5x
Sat, 11 Sep 2021	₩21.5t	₩2.6t	₩210.5b	14.4x
Mon, 09 Aug 2021	₩20.8t	₩2.6t	₩211.0b	15.3x
Sun, 02 May 2021	₩20.2t	₩2.6t	₩224.2b	14x
Wed, 03 Feb 2021	₩25.0t	₩2.6t	₩228.9b	10.8x
Sat, 07 Nov 2020	₩15.5t	₩2.6t	₩212.7b	50.9x
Fri, 31 Jul 2020	₩16.7t	₩2.4t	₩128.3b	70.1x
Mon, 04 May 2020	₩15.1t	₩2.2t	₩108.9b	55.8x
Thu, 06 Feb 2020	₩11.1t	₩2.0t	₩113.8b	15.1x
Sun, 10 Nov 2019	₩10.9t	₩1.8t	-₩117,623,252,410.00	96x
Sat, 03 Aug 2019	₩8.3t	₩1.7t	-₩103,445,052,160.00	83.1x
Tue, 07 May 2019	₩13.3t	₩1.6t	-₩109,740,151,950.00	228.2x
Fri, 08 Feb 2019	₩13.1t	₩1.5t	-₩68,154,162,550.00	484.8x

PE Ratio

484.8x

Fri, 08 Feb 2019

Current Industry PE: There are only 3 profitable companies in this industry, so there is insufficient data to make an industry-wide assessment of PE.

Past Earnings Growth: Total earnings for the Healthcare industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 20% per year. This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Trends

Which industries have driven the changes within the South Korean Healthcare Services industry?


Healthcare Services	-3.89%
Healthcare Facilities	-6.45%
Healthcare Distributors	-16.50%

Industry PE: Investors are most optimistic about the Healthcare Distributors industry even though it's trading below its 3-year average PE ratio of 104x. However analysts are expecting annual earnings growth of 24%, which is lower than the prior year's growth of 39% per year. So the market might believe that analysts are underestimating future growth.

Forecasted Growth: Analysts are most optimistic on the Healthcare Distributors industry, expecting annual earnings growth of 24% over the next 5 years. However this is lower than its past earnings growth rate of 39% per year.

	Company	Last Price	7D	1Y	Valuation
	A221800 U2Bio	₩33.95k	6.1% +₩3.7b	265.1%	n/a

Company

Last Price

Valuation

A221800 U2Bio

₩33.95k

6.1%
+₩3.7b

265.1%

n/a

Celltrion Group Announces Positive Results for Its Cocktail Therapy Candidates Including Neutralisation Data Against Omicron Variant

Celltrion Group announced results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529). The Phase I clinical trial is a randomised, double- blind and placebo- controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in 24 healthy subjects in Poland. The study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug- related adverse events (AEs). In an experiment conducted in partnership with the National Institutes of Health (NIH), CT-P63 showed strong neutralising activity against the Omicron variant based on structural analysis by X- ray crystallography and neutralisation data from pseudo- virus testing. Celltrion anticipates results of the SARS-CoV-2 Omicron variant assays and animal model studies by the end of the first quarter this year. In order to elicit potent neutralising antibody response against the new emerging variants, Celltrion previously identified a total of 38 potent neutralising antibodies against SARS-CoV-2 in which antibody candidate No. 32 (CT-P63) produced high neutralisation titres against new emerging strains. CT-P63 has previously been demonstrated to have neutralising activity against the most common variants, including the Alpha, Beta, Gamma and Delta variants.

South Korean (KOSPI) Healthcare Services Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

A091990

Celltrion Group Announces Positive Results for Its Cocktail Therapy Candidates Including Neutralisation Data Against Omicron Variant

A085660

Third quarter 2021 earnings released: EPS ₩62.00 (vs ₩26.00 loss in 3Q 2020)

A067630

Second quarter 2021 earnings released: ₩176 loss per share (vs ₩16.00 profit in 2Q 2020)

A118000

Investor sentiment improved over the past week

A032940

I Ran A Stock Scan For Earnings Growth And Wonik (KOSDAQ:032940) Passed With Ease

A043710

Is Seouleaguer (KOSDAQ:043710) A Risky Investment?

A078160

Is MEDIPOST (KOSDAQ:078160) Weighed On By Its Debt Load?

A221800

U2Bio CO. LTD., Annual General Meeting, Mar 29, 2021

A299170

WSI Co., Ltd. completed the acquisition of IBKS No.10 Special Purpose Acquisition Company (KOSDAQ:A299170) in a reverse merger transaction.